జర్నల్ ఆఫ్ సెల్యులార్ అండ్ మాలిక్యులర్ ఫార్మకాలజీ

నైరూప్య

PI3K/AKT/mTOR Pathway in ATLL: from Basic Biology to Preclinical Study

Jalal naghinezhad

Adult T-cell leukemia/ lymphoma (ATLL) is high resistance fatal malignancy which has a poor prognosis and exhibits resistance to conventional chemotherapy. The development of novel therapies for ATLL relies on a comprehensive understanding of the occurrences that result in cellular survival and proliferation regulating pathways that control growth signals is an emerging and complementary approach to ATL treatment. The PI3K/AKT/mTOR is a pivotal gatekeeper for cell growth, viability, migration, proliferation, and development drug resistance. Activation of PI3K, AKT, mTOR regulates important genes and proteins like mTOR, p53, NF-κB, P27, P21, S6K, FKHR and BAD. So this rout has a central role in handling cell cycle regulators, transcription factors and anti-apoptotic proteins. This review focuses on the role of PI3K/AKT/mTOR in ATL progression and development drug resistance.